title: Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
abstract: OBJECTIVE
  To report early experience of switching anti-tumor necrosis factor-a (TNF-alpha) therapy from infliximab to etanercept in patients with spondyloarthropathy (SpA) and psoriatic arthritis (PsA).
  
  
  METHODS
  Thirteen patients with various SpA (7 with ankylosing spondylitis and 6 with undifferentiated SpA) and 2 patients with PsA were receiving infliximab. Because they were experiencing inadequate response or adverse events, therapy was changed to etanercept. Patients were evaluated for response to the change in anti-TNF-alpha therapy at baseline, after 3 months, and then every 6 months.
  
  
  RESULTS
  During the mean 10-month followup after the change in therapy, 9 of 13 patients with SpA and both patients with PsA responded to etanercept and none experienced intolerance to this agent.
  
  
  CONCLUSIONS
  These data suggest that switching between anti-TNF-alpha drugs may be useful for patients with SpA who are unresponsive or intolerant to a first anti-TNF-alpha agent.
authors.affiliation: Department of Rheumatology, Henri Mondor Teaching Hospital, Créteil, France.
authors.forename: Caroline
authors.initials: C
authors.lastname: Delaunay
authors.forename: Valérie
authors.initials: V
authors.lastname: Farrenq
authors.forename: André
authors.initials: A
authors.lastname: Marini-Portugal
authors.forename: Jean-David
authors.initials: JD
authors.lastname: Cohen
authors.forename: Xavier
authors.initials: X
authors.lastname: Chevalier
authors.forename: Pascal
authors.initials: P
authors.lastname: Claudepierre
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000009:adverse effects; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D025242:Spondylarthropathies / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept